Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016
|
|
- Phyllis Austin
- 5 years ago
- Views:
Transcription
1 The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief Dept. of Medicine and Hypertension Institute and Director of The Brunner Institute for Cardiovascular Research Sackler Faculty of Medicine, Tel-Aviv University. The E. Wolfson Medical Center Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st,
2 Age is the predominant factor for CVD The population of the western world is aging, by 2030 there will be 71 million individuals over 65. Aging increases CV morbidity and mortality even in the absence of CVRF s. The risk of death from heart disease in the eighth decade is 60 times greater than in the 4 th decade. With aging the risk of overt, subclinical and silent (e.g. asymptomatic coronary atherosclerosis), disease increases dramatically. 2
3 The CV system aims to provide sufficient pressure and flow to the tissues at rest and during exercise. It s performance requires: Power and stroke capacity of the heart (Left Ventricle). Capacitance and inertial properties of the aorta (Aorta). Resistance capacity of the microcirculation (Resistance vessels, precapillaries). 3
4 Demographic Aspects During the recent decades longevity extended significantly. Life-span is now longer by more than 20 years compared to several decades ago. What are the consequences? 4
5 Aging. 5
6 6
7 1970 7
8 Essential (?) Hypertension Secondary hypertension will not be discussed here. It is another disease that one of it s manifestations is hypertension. Essential Hypertension is a misnomer- Blood pressure does not come by itself. It has a reason, pathogenesis and specific mechanisms of progression. Hypertension is a result of various pressor contributors to blood pressure like: o RAS, o Aldosterone, o Catecholaminergic system (SNS), o Humoral/metabolic effects (Obesity etc.) And their balance with vasodilator factors. 8
9 Contributors to Hypertension 9 Physiologic Morbid obesity Excess dietary sodium Excessive alcohol Sleep Apnea Humoral contributors to hypertension RAAS Aldosterone and mineralocorticoid Ht SNS Concurrent medications NSAIDs (low GFR) Sympathomimetics Illicit drugs Increased artery stiffness isolated systolic hypertension
10 Hypertensives Within Age Group (%) Age Distribution of Hypertensives in US 10 Population: NHANES III and the 1991 Census 30 26% 74% million hypertensives 26.0% of US population Age Groups (y) Franklin SS. J Hypertension. 1999;17(suppl 5):S29-S36.
11 Population With Hypertension (millions) Increased Prevalence of Hypertension in the United States from (NHANES III) to NHANES % increase, p< National Health and Nutrition Survey (NHANES) Nearly 1 in 3 Adults (31%) in the US Has Hypertension Fields, et al. Hypertension. 2004;44:398f
12 Cumulative Incidence of HTN in Women and Men Aged 65 Years 12 Risk of Hypertension % Men Women Years of Follow-up Vasan, et al. JAMA.2002;287:1003
13 Residual lifetime risk to develop hypertension 13 Vasan et al, JAMA 2002, 287, 1003
14 Pathogenesis of Systolic and Diastolic Hypertension Stroke Volume SYSTOLIC HYPERTENSION Central Artery Stiffness Arteriolar Constriction DIASTOLIC HYPERTENSION Inhibits Promotes 14
15 Arterial stiffening Gradual decrease in arterial elasticity that occurs in all subjects. The major cause for arterial stiffening is age, (Physiological aging, premature, pathological aging). Rate of progression of arterial stiffening is enhanced with presence of risk factors. Accumulation of Risk Factors, genetic properties and other mechanisms can magnify rate of arterial stiffening. 15
16 Blood Pressure: Generated by Ventricular Contraction Figure 15-4: Elastic recoil in the arteries 16
17 The heart pumps in short spurts. The compliant aorta stores this energy during ejection and releases it during diastole so that flow into the periphery continues throughout the cardiac cycle 17
18 DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) Mean SBP and DBP by Age and Race/Ethnicity for Men and Women (US Population Age 18 Years, NHANES III) Pulse pressure 110 Pulse pressure Men, Age (y) Women, Age (y) Burt VI, et al. Hypertension. 1995;25:
19 Artery Elasticity Index Hg x ml x 10) Large Artery Elasticity age (years) 19
20 Artery elasticity index Hg x ml x 100) Small Artery Elasticity age (years) 20
21 blood pressure systolic blood pressure age (years) 21
22 vascular resistence x sec x 10-5 ) systemic vascular resistence age (years) 22
23 Large artery arterial elasticity index Figure 1. Large artery arterial elasticity index by age group Age group (decades) 23
24 Small artery arterial elasticity index Figure 2. Small artery arterial elasticity index by age group age group (decades) 24
25 Elasticity (mmhg) Age Related Loss of Arterial Elasticity (Normotensives, free from obvious disease) 25 C1 and C2 decrease with age, the slope of C2 being greater. The change in C2 was independent of BP and may represent a more sensitive marker of the aging process. C1 (x 10) C2 (x 100) Age (years) McVeigh, Gary E.; Bratteli, Christopher W.; Morgan, Dennis J.; Alinder, Cheryl M.; Glasser, Stephen P.; Finkelstein, Stanley M.; Cohn, Jay N. Age-Related Abnormalities in Arterial Compliance Identified by Pressure Pulse Contour Analysis. HYPERTENSION 33: , June 1999.
26 Elasticity (mmhg) Elasticity Decreases as the Hypertensive State Increases Average and 95% Confidence Intervals C1 C Normotensive No Family History Normotensive Family History Hypertensive Treated, Controlled Hypertensive Untreated, Uncontrolled Prisant, L.M., Resnick, L.M., Hollenberg, S.M. Arterial Elasticity Among Normotensive Subjects and Treated and Untreated Hypertensive Subjects, Blood Pressure Monitoring 6: , 2001, Ref: 131
27 Why is aortic pressure pulsatile? With each ejection the aortic volume increases by one stroke volume 27
28 If aortic compliance were to decrease, pulse pressure will increase. 28
29 Aging reduces aortic compliance Pulse pressure naturally increases with age 120/80 Systolic hypertension >140 Compliance = volume/ pressure 29
30 Correlation between number of risk factors and arterial distensibility N = 803, mean age 30 y 30 Brachial artery distensibility ( % / mm Hg) Linear trend P < Brachial artery distensibility occurs long before clinical manifestations of CVD appear Number of CV risk factors 5 Bogalusa Heart Study Urbina EM et al. Am J Hypertens. 2005;18:
31 Peripheral arterial stiffness is associated with subclinical N = 256 atherosclerosis P < for trend 31 Thigh arterial compliance* Q1 Q2 Q3 Q4 MRI results Quartile of abdominal aorta wall thickening *Maximum volume change X 50 Brachial pulse pressure Herrington DM et al. Circulation. 2004;110:432-7.
32 Distribution of Hypertension Subtype in the Untreated Hypertensive Population by Age (NHANES III) 32 ISH (SBP 140 mm Hg and DBP <90 mm Hg) SDH (SBP 140 mm Hg and DBP 90 mm Hg) IDH (SBP <140 mm Hg and DBP 90 mm Hg) 100 } Diastolic Hypertension 17% 16% 16% 20% 20% 11% Frequency of hypertension subtypes in all untreated hypertensives (%) < Age (y) Numbers at top of bars represent the overall percentage distribution of untreated hypertension by age. Franklin et al. Hypertension. 2001;37:
33 Demography, Hypertension type Young-26% Elderly- 74% Franklin SS, 1999? % 80-90%????,
34 Hypertension type changes with age Arterial Stiffening Alpha: Variable Ageing + CVRF s 34
35 Hypertension type changes with age In Young Subjects? Humoral contribution Ageing + CVRF s 35
36 Hypertension type changes with age Arterial Stiffening Humoral contribution Ageing 36
37 Hypertension type changes with age Arterial Stiffening Humoral contribution Ageing Young subjects: Humoral factors Respond best to humoral blockers: -ACE/ARB -Mineralocorticoid antagonists? -BB? Stiff Arteries Respond best to: -CCB s -Diuretics 37
38 Stiffness becomes predominant gradually with age Young Elderly Transition zone: both humoral and stiffening present Young, fast stiffeners (premature stiffening Elderly, slow stiffeners 38
39 JNC Reclassification of BP Based on Risk ategory SBP (mm Hg) JNC VI DBP (mm Hg) Category JNC 7 SBP (mm Hg) 39 DBP (mm Hg) Optimal Normal Hi-normal <120 and 80 Normal <120 and and or Prehypertension or Hypertension Stage or Stage or Stage 2 Stage or or Stage or 100 Source for JNC VI: Arch Intern Med. 1997;157: Adapted with permission from Chobanian AV et al. Hypertension. 2003;42:
40 JNC Reclassification of BP Based on Risk ategory SBP (mm Hg) JNC VI DBP (mm Hg) Category JNC 7 SBP (mm Hg) 40 DBP (mm Hg) Optimal Normal Hi-normal <120 and 80 Normal <120 and and or Prehypertension or Hypertension Stage or Stage or Stage 2 Stage or or Stage or 100 Source for JNC VI: Arch Intern Med. 1997;157: Adapted with permission from Chobanian AV et al. Hypertension. 2003;42:
41 2013 ESH-ESC Guidelines for the management of Hypertension Evaluation of global CV risk Organ Damage 41
42 2013 ESH-ESC Guidelines for the management of Hypertension Evaluation of global CV risk Organ Damage 42
43 Is there a J curve for increased CV events? 43 CV events DBP
44 Is there a J curve for increased CV events? 44 CV events Do we really lower DBP or stiffening does it by itself??? DBP
45 BP-Lowering Treatment Trialists Comparisons of Different Active Treatments BP Difference (mm Hg) Relative Risk RR (95% CI) Major CV events ACEI vs D/BB CA vs D/BB ACEI vs CA CV mortality ACEI vs D/BB CA vs D/BB ACEI vs CA Total mortality ACEI vs D/BB CA vs D/BB ACEI vs CA 2/0 1/0 1/1 2/0 1/0 1/1 2/0 1/0 1/ (0.98, 1.07) 1.04 (0.99, 1.08) 0.97 (0.95, 1.03) 1.03 (0.95, 1.11) 1.05 (0.97, 1.13) 1.03 (0.94, 1.13) 1.00 (0.95, 1.05) 0.99 (0.95, 1.04) 1.04 (0.98, 1.10) 0.5 Favors 1.0 Favors 2.0 First Listed Second Listed Blood Pressure Lowering Treatment Trialists Collaboration. Lancet. 2003;362:
46 BP-Lowering Treatment Trialists Comparisons of Different Active Treatments BP Difference (mm Hg) Relative Risk RR (95% CI) Major CV events ACEI vs D/BB CA vs D/BB ACEI vs CA CV mortality ACEI vs D/BB CA vs D/BB ACEI vs CA Total mortality ACEI vs D/BB CA vs D/BB ACEI vs CA 2/0 1/0 1/1 2/0 1/0 1/1 2/0 1/0 1/ (0.98, 1.07) 1.04 (0.99, 1.08) 0.97 (0.95, 1.03) 1.03 (0.95, 1.11) 1.05 (0.97, 1.13) 1.03 (0.94, 1.13) 1.00 (0.95, 1.05) 0.99 (0.95, 1.04) 1.04 (0.98, 1.10) 0.5 Favors 1.0 Favors 2.0 First Listed Second Listed Blood Pressure Lowering Treatment Trialists Collaboration. Lancet. 2003;362:
47 Algorithm Hypertension type changes with age Arterial Stiffening Humoral contribution Ageing Determine the type of Ht Young, Humoral / / Elderly, Stiff Age Diastolic Pressure Pulse Pressure ISH/DSH/SDH Arterial Stiffness (PWV, Central P, Aug Index) Young subjects: Humoral factors Respond best to humoral blockers: ACE ARB -BB? Stiff Arteries Respond best to: -CCB s -Diuretics 47
48 48
Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationWhich method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호
Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Arterial stiffness Arterial stiffness is inversely related to arterial
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationImpedance Cardiography (ICG) Application of ICG for Hypertension Management
Application of ICG for Hypertension Management 1mA @ 100 khz Impedance Cardiography (ICG) Non-invasive Beat-to-beat Hemodynamic Monitoring Diastole Systole Aortic valve is closed No blood flow in the aorta
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationOsama Sanad (MD) Prof. of Cardiology Benha University 2016
Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationTODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients
CARDIOVASCULAR TECHNOLOGY AND INDICATION SERVICE TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients SERIES Hypertension Management in the
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPreventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex
Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationArterial function and longevity Focus on the aorta
Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling
More information3 Aging, Arterial Stiffness,
Chapter 3 / Mechanisms of Hypertension 23 3 Aging, Arterial Stiffness, and Systolic Hypertension Joseph L. Izzo, Jr., MD CONTENTS INTRODUCTION POPULATION STUDIES PATHOPHYSIOLOGY NONINVASIVE MEASUREMENT
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More information2009 Shattuck Lecture
2009 Shattuck Lecture The Hypertension Paradox: Remarkable Advances in Therapy but Continued Increase in Prevalence of Uncontrolled Hypertension Disclosures: Dr. Chobanian has no conflicts to disclose
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationEpidemiology of Hypertension
Epidemiology of Hypertension Stanley S. Franklin, MD, FACP, FACC Clinical Professor of Medicine University of California at Irvine Associate Medical Director UCI Heart Disease Prevention Program Irvine,
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationThe Hypertension Clinic is a part of the Internal Medicine
Original Article Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience OBJECTIVE: The Hypertension Registry at the Bangkok Hospital Medical Center was established
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationDanno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?
Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationSpecial Lecture 10/28/2012
Special Lecture 10/28/2012 HYPERTENSION Dr. HN Mayrovitz Special Lecture 10/28/2012 Arterial Blood Pressure (ABP) - Definitions ABP Review Indirect Oscillographic Method Resistance (R), Compliance (C)
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationControlling Hypertension in Primary Care: Hitting a moving target?
Controlling Hypertension in Primary Care: Hitting a moving target? David J. Hyman, MD,MPH Professor of Medicine and Family & Community Medicine Chief, Section General Medicine Baylor College of Medicine
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHow to Manage Resistant Hypertension Min Su Hyon, MD
How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine Definition Resistant to conventional medical therapy Definition
More informationESSENTIAL HYPERTENSION
E S S E N T I A L H Y P E R T E N S I O N Elevated blood pressure is one of the most important causes of cardiovascular disease. J A Ker MB ChB, MMed, MD Professor and Deputy Dean Faculty of Health Sciences
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationIsolated Systolic Hypertension in the elderly. Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg
Isolated Systolic Hypertension in the elderly Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Case no 1 Man aged 75, from Kosovo, in CH since 1.5 years Former smoker (45 PY) BP:
More informationArterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski
Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationHypertension mechanisms
הטיפול בלחץ דם בעזרת תרופות מישלב Hypertension mechanisms ESH Task Force Document. J Hypertens 2009 The history of development of antihypertensive drugs ESH Task Force Document. J Hypertens 2009 הטיפול
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationWhat s all the Fuss?
HYPERTENSION: What s all the Fuss? Presenter name: Presenter title: Department: Institute Marc A. Pohl, MD Ray W. Gifford Chair in Hypertension, and Head, Section of Clinical Hypertension Nephrology and
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationWhen should blood pressure be lowered? Should treatment be guided by blood pressure values or total cardiovascular risk?
OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Editorial J Hypertens Res (2016) 2(2):47 51 When should blood pressure be lowered? Should treatment be guided
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationmajor public health burden
HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More information